Dr Lennard Lee is a consultant medical oncologist, clinical academic and national research leader whose expertise lies in the delivery of large-scale, high-impact research programmes that translate scientific innovation into real-world patient benefit. Since 2020, he has played a leading role in the design, mobilisation and delivery of nationally strategic initiatives spanning cancer vaccines, artificial intelligence, genomics and diagnostics research.

His particular strength lies in transforming ambitious and complex ideas into reality. He is highly skilled at bringing together scientists, clinicians, policymakers, industry partners and patients around a shared vision, aligning diverse interests to achieve common goals. Through this ability, he has consistently enabled programmes that push the boundaries of biomedical research and accelerate the translation of ideas into patient impact.

As the national lead for the UK Cancer Vaccine Advance, Lennard has shaped the sovereign strategy to advance cancer vaccine development, clinical trials and patient access across the United Kingdom. He founded and established the NHS Cancer Vaccine Launchpad, a national initiative designed to streamline recruitment into cancer vaccine studies and support the ambition of enrolling 10,000 patients into cancer vaccine trials by 2030.

Lennard also leads the UK Cancer Vaccine AI Scientist and Supercomputing Project, a national flagship programme combining sovereign AI supercomputing, advanced robotics and AI Scientist systems to accelerate the discovery, validation and manufacture of next-generation intelligent cancer vaccines. This project has over 2,500 supporters and is referenced in the 10-year national cancer plan as a project that would help the country achieve world-class research excellence. It is also listed in the Government’s 2026 AI for Science Strategy and backed by ARIA, the UK’s high-risk, high-reward research funder, ARIA, as well as supported by MRC, UKRI, DSIT and Cancer Research UK.

Lennard's modus operandi is to create, develop and empower world-class teams focused on improving cancer care and advancing medical research. Working with openness, integrity and humility, he believes that ambitious goals are achieved when talented people are united behind a shared vision. His approach centres on aligning researchers, clinicians, patients, industry and policymakers around strategically important challenges, creating the momentum and trust required to deliver lasting impact.

His contributions have been recognised through numerous awards, including the National ACP McElwain Prize, the IAP Outstanding Young Physicians Award, the Department for Science, Innovation and Technology Superhero Award, and the Government Office for Science Infinity Award. With more than 75 peer-reviewed publications and extensive national and international media engagement, Lennard leads programmes that advance cancer research, strengthen UK scientific capability and deliver tangible benefits for patients.

His work and research have been featured by the BBC, ITV, Daily Mail, Tortoise Media and international news organisations. He is a highly effective communicator, demonstrated through his public engagement activities and his role within IndieSAGE. He is widely recognised for his ability to build productive relationships across academia, industry, patient groups, government and healthcare systems, helping diverse communities work together towards common goals.

In addition to his work on cancer vaccines, Lennard has made significant contributions to several nationally important research programmes. As founder of the award-winning UK Coronavirus Cancer Monitoring Project, he established a population-scale initiative linking data from 90 hospitals to understand and improve outcomes for cancer patients during the pandemic. Within the UK Lateral Flow Moonshot programme, he helped support the national scale-up of lateral flow coronavirus testing. In the NHS, he led delivery of the record-breaking NHS-Galleri Trial, embedding the study across 70 hospitals and randomising 140,000 participants in just 10.2 months to evaluate a multi-cancer early detection blood test capable of identifying more than 50 cancer types.

Working closely with government, research organisations and industry partners, he plays a key role in connecting the University of Oxford with emerging technologies that have the potential to improve patient outcomes. Through this work, he has positioned the United Kingdom at the forefront of AI-enabled biomedical research, clinical innovation and next-generation healthcare delivery.